Objectives
After participating in this educational activity, attendees should be able to:
1| Discuss cocaine use disorder and its impact nationally and statewide.
2| Review the current pharmacotherapy available for cocaine use disorder.
3| Evaluate the efficacy of buprenorphine-naloxone and naltrexone in treating cocaine use disorder.
4| Apply literature to clinical practice as appropriate
2| Review the current pharmacotherapy available for cocaine use disorder.
3| Evaluate the efficacy of buprenorphine-naloxone and naltrexone in treating cocaine use disorder.
4| Apply literature to clinical practice as appropriate
Presenter(s):
Kathryn Higgins, PharmD
Kathryn Higgins, PharmD
PGY1 Community Based Pharmacy Resident
Baystate Medical Center
Name | Role | Financial Relationship Disclosures | Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation? |
---|---|---|---|
Kathryn Higgins, PharmD | Speaker/Author | No relevant relationships with ineligible companies to disclose | No |
Session date:
02/03/2025 - 2:00pm to 3:00pm EST
Add to calendar:
- 1.00 ACPE Contact Hours